Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Trial details
- Registry ID
- NCT05733598
- Phase
- Phase 2
The FDA approved Durvalumab (Imfinzi) on 1 May 2017.
Drug identity checked against registry records
Also recorded as Imfinzi
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCNCT05733598 | Replimune, Inc. | Phase 2 | Recruiting | 2027-12-01Estimated |
| A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCNCT07459634 | Jazz Pharmaceuticals | Phase 2 | Recruiting | 2029-08-04Estimated |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsNCT05712356 | LSTA | Phase 2 | Completed | 2026-04-05Actual |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerNCT06282575 | Jazz Pharmaceuticals | Phase 3 | Recruiting | 2028-12-01Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2017-05-01Day | Durvalumab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761069", "applicant_as_listed_by_fda": "ASTRAZENECA UK LTD", "brand_names": ["IMFINZI"], "active_ingredients": ["DURVALUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20170501", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |